Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature

L. Pinkas, P. D. Robins, L. A. Forstrom, B. P. Mullan, D. W. Mahoney

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

A retrospective study was carried out to determine the diagnostic value of OncoScint CR/OV immunescintigraphy in assessing patients with suspected recurrence of carcinoma of the colon and ovary. The scintigraphic results of 31 patients were compared with surgical and histopathological findings, conventional radiological examinations and clinical disease outcome over an average 3-year follow-up. Detected lesions were divided by location into hepatic or extrahepatic and the latter group was classified as local recurrence at the resection site, pelvic or abdominal regional lymph node involvement and distant metastatic disease. The combined sensitivity and accuracy of immunoscintigraphy in the detection of extrahepatic disease was significantly higher than that of cross-sectional radiological imaging (87% and 83% vs 44% and 53% respectively) with equal specificity of 74%. Scintigraphy identified 14 (36%) of 39 extrahepatic malignant lesions not diagnosed by conventional radiological techniques and influenced therapeutic planning in 8 (26%) of 31 patients studied. In the liver, conventional imaging had a significantly higher detection rate than immunoscintigraphy (sensitivity 93% vs 28%). In conclusion, these results show that OncoScint scintigraphy is a sensitive method for the detection of local recurrence and extrahepatic metastases in colorectal and ovarian carcinoma and has an important role in the therapeutic decision-making process.

Original languageEnglish (US)
Pages (from-to)689-696
Number of pages8
JournalNuclear medicine communications
Volume20
Issue number8
DOIs
StatePublished - Aug 1999

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature'. Together they form a unique fingerprint.

Cite this